The oxytocin receptor (OXTR) is a G protein-coupled receptor that mediates the effects of oxytocin, a neuropeptide involved in social bonding, childbirth, and stress regulation. OXTR antibodies are essential tools for studying the receptor's expression, localization, and function in various tissues, including the brain, uterus, and heart. These antibodies are typically developed in host species (e.g., rabbits, mice) using synthetic peptides or recombinant OXTR proteins as immunogens. They enable techniques like immunohistochemistry, Western blotting, and flow cytometry to map OXTR distribution in physiological and pathological contexts, such as autism spectrum disorders, anxiety, and reproductive health. Challenges in OXTR antibody validation arise from sequence homology with vasopressin receptors and species-specific variations. Recent advances in CRISPR-based validation and knockout controls have improved specificity. Commercial OXTR antibodies vary in clonality (monoclonal/polyoclonal), epitope targets, and applications, requiring careful selection based on experimental models. Research using these antibodies has expanded insights into oxytocin's role in neuromodulation, pair bonding, and potential therapeutic applications for social dysfunction. However, inconsistent reporting of antibody validation in studies underscores the need for standardized protocols to ensure reproducibility.